

**Attendees**

Member	Role at PINTAD and Background
Fabien Ricard	PINTAD chair. New York area. Nuclear Medicine Radiologist. Director, global Clinical Development Radiology, Bayer.
Brenda Kurland	PINTAD co-chair. From academia. PhD in Biostats. Cognitive psychology, study design, longitudinal and correlative data. Fred Hutchinson cancer center in the clinical research division. Solid tumor oncology and liquid tumors. FES and FDG PET. QIBA. Pre-clinical PET. Now at ERT.
Julie Gillis	Communication manager. Massachusetts. Nuclear Medicine Technologist. 10 + years in the CRO space.
Melissa Burkett	Steering Committee. Nuclear Medicine and PET, human and animal research with a large focus on neurology. Applications specialist at GE. Molecular imaging consultant at GE.
Colin Miller	Steering Committee. Physiologist. Been in the imaging sector for many years. Founded Bioclinica. Bracken group. Recently developing new radiopharmaceuticals.
Greg Goldmacher	Steering Committee. Massachusetts. Diagnostic radiologist. PhD in neuroscience and neurophysiology. Worked for ICON. Runs clinical imaging for Merk.
Annette Schmid	Steering Committee. Vermont. Honor member, former PINTAD lead.
Can Akgun ("John")	Steering Committee. Not in attendance (excused)

**Agenda**

- **Welcome**                      **5'**
- **New Team**                      **15'**
- **Operations**                      **10'**
- **Vision**                              **15'**
- **Topics**                              **15'**

Agenda Topic	Minutes
<b>Welcome</b>	-Fabien, chair, welcomed all participants and presented the new structure of the PINTAD with Brenda as co-chair, Julie as communication specialist, and a steering committee including Annette, Can, Colin, Greg and Melissa. -Each participant introduced him(her)self. It was acknowledged that the team has very complementary backgrounds. -One additional member may join the SC at a later date but was not yet disclosed.
<b>New Team</b>	See above

Agenda Topic	Minutes
<b>Operations</b>	<ul style="list-style-type: none"> <li>• Handover PINTAD will be the last Friday of July via WebEx. Annette to organize. New team will then take over organization.</li> <li>• PINTAD Schedule:               <ul style="list-style-type: none"> <li>○ Exclude August</li> <li>○ Keep last Friday of every month</li> <li>○ Keep 11am-12pm EST</li> </ul> </li> <li>• PINTAD Meeting Format               <ul style="list-style-type: none"> <li>○ Teams</li> </ul> </li> <li>• Structure of PINTAD Meetings               <ul style="list-style-type: none"> <li>○ LT to present speaker</li> <li>○ Moderator will be someone from the steering committee based on expertise/topic etc.</li> <li>○ Conclusion poll – not needed every time – Julie to monitor drop off rate</li> <li>○ Minutes and presentation storage/website? Not discussed</li> <li>○ Keep presentations to 30-40 minutes so there is time for discussion/questions</li> <li>○ Occasional panel meeting or Journal Club</li> <li>○ Rotating oncology/non-oncology topics (one every ~3-4 meetings)</li> <li>○ Incorporate early phase/clinical topics (not preclinical)</li> </ul> </li> </ul>
<b>Vision</b>	<p><b>More engagement from global audience, clinical personnel, and regulatory experts:</b></p> <ul style="list-style-type: none"> <li>• There are many people in pharma companies interested in application of imaging, imaging data, how it impacts their work (e.g. translational scientists)</li> <li>• Engage clinicians with topics on translational imaging, biomarkers, AI (Dr. Goldmacher knows people in his translational oncology group who may be interested)</li> <li>• Depending on the topic, regulators are drawn in to participate</li> <li>• Harder to get Europe on board because the time is late for them on Fridays               <ul style="list-style-type: none"> <li>○ Hold meetings at specific times of the year (every 6 months or quarterly) during another day/time to invite/encourage global counterparts and to get EU/EMA engagement</li> <li>○ Focus on regulatory topics</li> </ul> </li> </ul> <p><b>Working groups for specific topics</b></p> <ul style="list-style-type: none"> <li>• Do-able if volunteers are willing to take the lead</li> </ul> <p><b>Publication Strategy</b></p> <ul style="list-style-type: none"> <li>• Variability white paper coming (Dr. Schmid and Dr. Miller)</li> <li>• PROLOG white paper coming</li> <li>• Incidental findings publication may be coming</li> <li>• Create a bank of publications on behalf of PINTAD</li> </ul> <p><b>How to differentiate and add value vs. other imaging groups</b></p> <ul style="list-style-type: none"> <li>• Other groups are more technical/scientific</li> <li>• PINTAD is more industry focused</li> </ul>

PINTAD  
 Internal Team Meeting Minutes  
 08-July-2020

Agenda Topic	Minutes
	<p><b>Visibility</b></p> <ul style="list-style-type: none"> <li>• Other companies such as CRO doing free webinars that may look like PINTAD activity, PINTAD will need to be visible to not lose engagement from members</li> <li>• Create a Linked In</li> <li>• Streamline registration process</li> </ul>
<b>Topics</b>	<ul style="list-style-type: none"> <li>• IT-RECIST- Dr. Goldmacher</li> <li>• iRECIST (other immune)             <ul style="list-style-type: none"> <li>○ iRECIST presented by Dr. Goldmacher in 2015</li> <li>○ <a href="https://5148ca70-7f75-4b5f-ad2a-7a9b66890029.filesusr.com/ugd/7a7b42_4d71c6e956854bc39c1678c2e104a129.pdf">https://5148ca70-7f75-4b5f-ad2a-7a9b66890029.filesusr.com/ugd/7a7b42_4d71c6e956854bc39c1678c2e104a129.pdf</a></li> </ul> </li> <li>• RECIL (Anas Younes? at AstraZeneca)</li> <li>• CNS RECIST vs. RANO BM</li> <li>• Beyond RECIST 1.1, e.g. pediatric assessments</li> <li>• AI – radiomics (would be good to establish best practices, important topic, focus on practical applications and appropriate endpoints)</li> <li>• Impact of COVID –CROs have presented, presented at ASCO, other groups have task forces. Still, PINTAD is a good platform to collect feedback from community and share with FDA.</li> <li>• Theragnostics</li> <li>• MSK</li> <li>• MS</li> <li>• New imaging biomarkers and response criteria</li> </ul>

Meeting ran 10 minutes over.